Show simple item record

dc.contributor.authorDixon-Jimenez, Amy C
dc.date.accessioned2017-03-28T04:31:19Z
dc.date.available2017-03-28T04:31:19Z
dc.date.issued2016-08
dc.identifier.otherdixon-jimenez_amy_c_201608_ms
dc.identifier.urihttp://purl.galileo.usg.edu/uga_etd/dixon-jimenez_amy_c_201608_ms
dc.identifier.urihttp://hdl.handle.net/10724/36703
dc.description.abstractUp to 41% of cats diagnosed with hypertrophic cardiomyopathy will develop systemic arterial thromboembolism (ATE). ATE is a devastating sequela since only 37% to 45% of cats survive their first thromboembolic event. Currently available treatments include the use of antiplatelet agents such as aspirin and/or clopidogrel or anticoagulant medications such as unfractionated or low-molecular weight heparins. However, these treatments have not been shown to prevent primary ATE and clopidogrel is associated with a 49% recurrent event rate. Rivaroxaban is an orally administered direct inhibitor of activated Factor X that is approved for prophylaxis of deep vein thrombosis, pulmonary embolism, and for the prevention of stroke in patients with non-valvular atrial fibrillation and acute coronary syndrome. The primary goal of this study was to evaluate the pharmacokinetic and pharmacodynamic profile of single and multiple oral doses of RVX in healthy adult cats.
dc.languageeng
dc.publisheruga
dc.rightspublic
dc.subjectcoagulation, cardiomyopathy, thromboembolism, hemostasis
dc.titleThe evaluation of rivaroxaban
dc.title.alternativea new oral anticoagulant in cats
dc.typeThesis
dc.description.degreeMS
dc.description.departmentVeterinary and Biomedical Sciences
dc.description.majorVeterinary and Biomedical Sciences
dc.description.advisorBenjamin Brainard
dc.description.committeeBenjamin Brainard
dc.description.committeeGregg Rapoport
dc.description.committeeSteven Holladay


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record